Aptose Biosciences (APTO)
(Delayed Data from NSDQ)
$1.20 USD
+0.01 (0.84%)
Updated May 3, 2024 04:00 PM ET
After-Market: $1.20 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Aptose Biosciences, Inc. [APTO]
Reports for Purchase
Showing records 21 - 40 ( 144 total )
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; We Believe Upcoming ASH Should Revitalize Shares; Target Increased to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
HM43239 Beefs Up a Growing Portfolio of Anti-Leukemic Assets
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Crunch Time Coming for Assets as Company Expands; Keep an Eye On
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; Incremental Updates in Three Phase 1a/b Trials
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Luxeptinib Continues to Build a Promising Profile in Very Tough Populations at EHA
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; Three Phase 1a/b Trials Advance; Comprehensive Update Expected at EHA
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2020 Results; Dose Escalation in Luxeptinib Trials Continues; AML CR Excites with All Eyes on EHA
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CG-806 ASH Update Continues Crawl Along; Leading Indicators Point to Likely Evolving Responses
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CG-806 Begins Treatment of r/r AML at Targeted Efficacious Dose; Key Updates Expected at ASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 results; ASH Can''t Get Here Fast Enough
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CG-806 Continues to Build a Promising Profile at EHA
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Results; Blocking and Tackling Continues as Trials Expand
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Incremental AACR Data; Push for Responses Continues
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2019 Results; Anticipating the Switch From PK/PD to Responses Hopefully Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Our Take on CG-806''s Development in CLL: Addressing Therapy Resistance In Combination Regimens
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
KOLs Views Toward CG-806 Clinical Development in AML; Target Increased to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Applaud ArQule for Sure, But Focus on the ''Tree''; Aptose Strikes Right Balance in Targeting With CG-806
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J